Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome

American Journal of Gastroenterology

Volumn 106, Issue 7, 2011, Pages 1290-1298

  Cremon, Cesare ^a,e   Carini, Giovanni ^a   Wang, Bingxian ^b   Vasina, Valentina ^a   Cogliandro, Rosanna F ^a   De Giorgio, Roberto ^a   Stanghellini, Vincenzo ^a   Grundy, David ^c   Tonini, Marcello ^d   De Ponti, Fabrizio ^a   Corinaldesi, Roberto ^a   Barbara, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b McMaster Brain Body Institute   (Canada)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON; SEROTONIN;

ABDOMINAL PAIN; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CLINICAL ARTICLE; COLON BIOPSY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ELECTROPHYSIOLOGY; DISEASE SEVERITY; ENTEROCHROMAFFIN CELL; ENZYME IMMUNOASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IRRITABLE COLON; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SENSORY NERVE CELL; SEROTONIN RELEASE;

ABDOMINAL PAIN; ADULT; ANIMALS; CELL COUNT; ENTEROCHROMAFFIN CELLS; FEMALE; HISTAMINE; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; JEJUNUM; MALE; MAST CELLS; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TRYPTASES; VISCERAL AFFERENTS; YOUNG ADULT;

EID: 79960055079     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.86     Document Type: Article

References (49)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Barbara G, De Giorgio R, Stanghellini V et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20 (Suppl 2): 1-9. (Pubitemid 39237523)
3. Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-98. (Pubitemid 350206308)
4. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414. (Pubitemid 46127672)
5. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007; 19 (Suppl 2): 25-31. (Pubitemid 47037963)
6. De Giorgio R, Barbara G, Furness JB e t al. Novel therapeutic targets for enteric nervous system disorders. Trends Pharmacol Sci 2007; 28: 473-81. (Pubitemid 47368703)
7. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53: 1520-35. (Pubitemid 39272827)
8. Tonini M. 5-Hydroxytryptamine Effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil 2005; 17: 637-42. (Pubitemid 41400711)
9. Ford AC, Brandt LJ, Young C et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and metaanalysis. Am J Gastroenterol 2009; 104: 1831-43.
10. Zighelboim J, Talley NJ, Phillips SF et al. Visceral perception in irritable bowel syndrome: rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-27.
11. Kreis ME, Jiang W, Kirkup AJ et al. Cosensitivity of vagal mucosal afferents to histamine and 5-HT in the rat jejunum. Am J Physiol Gastrointest Liver Physiol 2002; 283: G612-7. (Pubitemid 34920348)
12. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59. (Pubitemid 29445893)
13. Camilleri M, Northcutt AR, Kong S et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40. (Pubitemid 30162805)
14. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 42-6. (Pubitemid 28228386)
15. Houghton LA, Atkinson W, Whitaker RP et al. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003; 52: 663-70. (Pubitemid 36528867)
16. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57. (Pubitemid 40488343)
17. Atkinson W, Lockhart S, Whorwell PJ et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43. (Pubitemid 43049833)
18. Houghton LA, Atkinson W, Lockhart C et al. Sigmoid-colonic motility in health and irritable bowel syndrome: a role for 5-hydroxytryptamine. Neurogastroenterol Motil 2007; 19: 724-31. (Pubitemid 47312399)
19. Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-64. (Pubitemid 38736329)
20. Faure C, Patey N, Gauthier C et al. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology 2010; 139: 249-58.
21. Camilleri M, Andrews CN, Bharucha AE et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 2007; 132: 17-25. (Pubitemid 46108754)
22. Kerckhoff s AP, Ter Linde JJ, Akkermans LM et al. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil 2008; 20: 900-7. (Pubitemid 352019709)
23. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl 2): II43-7. (Pubitemid 29434812)
24. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702. (Pubitemid 38298317)
25. De Giorgio R, Arakawa J, Wetmore CJ et al. Neurotrophin-3 and neurotrophin receptor immunoreactivity in peptidergic enteric neurons. Peptides 2000; 21: 1421-6.
26. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
27. Lee E, Schiller LR, Fordtran JS. Quantification of colonic lamina propria cells by means of a morphometric point-counting method. Gastroenterology 1988; 94: 409-18. (Pubitemid 18054778)
28. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37. (Pubitemid 46108761)
29. Grossi G, Bargossi A, Sprovieri G et al. Full automation of serotonin determination by column switching and HPLC. Chromatographia 1990; 30: 61-8.
30. Wang B, Glatzle J, Mueller MH et al. Lipopolysaccharide-induced changes in mesenteric afferent sensitivity of rat jejunum in vitro: role of prostaglandins. Am J Physiol Gastrointest Liver Physiol 2005; 289: G254-60. (Pubitemid 41022751)
31. Ky ö sola K, Penttil ä O, Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol 1977; 12: 363-7. (Pubitemid 8101701)
32. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
33. Dunlop SP, Jenkins D, Neal KR et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9. (Pubitemid 37500429)
34. Cremonini F, Camilleri M. Of actors, bolting horses, and drops in oceans!. Gut 2003; 52: 619-21. (Pubitemid 36528858)
35. Ohman L, Simr én M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
36. Coleman NS, Foley S, Dunlop SP et al. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006; 4: 874-81. (Pubitemid 43994540)
37. Minderhoud IM, Oldenburg B, Schipper ME et al. Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission. Clin Gastroenterol Hepatol 2007; 5: 714-20. (Pubitemid 46830050)
38. Linden DR, Chen JX, Gershon MD et al. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003; 285: G207-16. (Pubitemid 36736404)
39. O ' Hara JR, Ho W, Linden DR e t al. Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol 2004; 287: G998-G1007. (Pubitemid 39423692)
40. Wheatcroft J, Wakelin D, Smith A et al. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17: 863-70. (Pubitemid 41748282)
41. Prior A, Read NW. Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175-80. (Pubitemid 23109464)
42. Delvaux M, Louvel D, Mamet JP et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55. (Pubitemid 28428949)
43. Cenac N, Andrews CN, Holzhausen M et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007; 117: 636-47. (Pubitemid 46348522)
44. Buhner S, Li Q, Vignali S et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-34.
45. Hillsley K, Kirkup AJ, Grundy D. Direct and indirect actions of 5-hydroxytryptamine on the discharge of mesenteric afferent fibres innervating the rat jejunum. J Physiol 1998; 506 (Part 2): 551-61. (Pubitemid 28048379)
46. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-9.
47. Camilleri M, Bueno L, De Ponti F et al. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006; 130: 1421-34.
48. Houghton LA, Brown H, Atkinson W et al. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: Effects of gender and menstrual status. Aliment Pharmacol Ther 2009; 30: 919-29.
49. Dunlop SP, Jenkins D, Spiller RC. Age-related decline in rectal mucosal lymphocytes and mast cells. Eur J Gastroenterol Hepatol 2004; 16: 1011-5.